Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary Conditions
NCT07915882, Not applicable, Recruiting, Michael Incze
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary Conditions | ClinicalTrials.gov |
| NCT number | NCT07915882 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 45 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Michael Incze | ClinicalTrials.gov |
| Conditions | Methamphetamine-Associated Heart Failure, Methamphetamine-Associated Pulmonary Arterial Hypertension | ClinicalTrials.gov |
| Interventions | Increasing control over stimulant use and physical health through incentivized rehabilitation, Usual Care | ClinicalTrials.gov |
| First posted | 2026-11-04 | ClinicalTrials.gov |
| Last updated | 2026-11-04 | ClinicalTrials.gov |
Registered outcomes 15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in metabolic equivalents (METs) | Baseline, 1, 3, and 6 months | Change in METs before and after the intervention measured via Duke Activity Status Indicator (DASI) | ClinicalTrials.gov |
| Primary | Change in self-reported substance use | Baseline, 1, 3, and 6 months | Change in self-reported substance use amount and frequency via Timeline Follow Back (TLFB) | ClinicalTrials.gov |
| Secondary | Quality of Life - Short Form 20 | Baseline, 1, 3, and 6 months | Measure of participants' quality of life using the Short Form 20 (SF-20) questionnaire. The score range of this survey is 0-100, with higher scores indicating better overall quality of life. | ClinicalTrials.gov |
| Secondary | Quality of Life - Kansas City Cardiomyopathy Questionnaire-12 | Baseline, 1, 3, and 6 months | Measure of participant's quality of life using the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12). The score range of this survey is 0-100, with higher scores indicating better functioning and less limitation from heart failure symptoms. | ClinicalTrials.gov |
| Secondary | Self-Efficacy Related to Avoiding Substance Use with the Drug Avoidance Self-Efficacy Scale (DASES). The score range of this survey is 0-96, with higher scores indicating better self-efficacy to avoid substance use. | Baseline, 1, 3, and 6 months | Measure of self-efficacy to avoid substance use with the Drug Avoidance Self-Efficacy Scale (DASES). | ClinicalTrials.gov |
| Secondary | Recovery Capital using the Brief Assessment of Recovery Capital (BARC-10) questionnaire | Baseline, 1, 3, and 6 months | Measure of the internal and external resources (recovery capital) that help initiate and sustain recovery from substance use disorder, using the Brief Assessment of Recovery Capital (BARC-10) questionnaire. The score range of this survey is 10-60, with higher scores indicating a greater amount of recovery capital. | ClinicalTrials.gov |
| Secondary | Contingency Management App Engagement | 3 months and 6 months | Number of weekly App Log-Ins, Contingency Management Draws and Earnings | ClinicalTrials.gov |
| Secondary | Hospital Readmissions in the Past 30 Days | Baseline, 1, 3, and 6 months | Self-Reported Hospital admissions in the past 30 days using Timeline Follow Back | ClinicalTrials.gov |
| Secondary | Emergency Department Visits in the Past 30 days | Baseline, 1, 3, and 6 months | Self-Reported number of ED visits in the past 30 days using Timeline Follow Back | ClinicalTrials.gov |
| Secondary | Urgent Care Visits in the Past 30 Days | Baseline, 1, 3, and 6 months | Self-Reported number of urgent care visits in the past 30 days using Timeline Follow Back | ClinicalTrials.gov |
| Other | INSPIRE Acceptability assessed via 4-item Intervention Acceptability Measure (IAM) | immediately after the intervention (12 weeks from randomization) | Measure of INSPIRE acceptability through the IAM survey collected one time from all patient participants one time at the end of the intervention | ClinicalTrials.gov |
| Other | INSPIRE Appropriateness assessed via 4-item Appropriateness of Intervention Measure (AIM) | immediately after the intervention (12 weeks from randomization) | Measure of INSPIRE appropriateness through Appropriateness of Intervention Measure (AIM) collected one time from all patient participants one time at the end of the intervention | ClinicalTrials.gov |
| Other | Reach of the Intervention Over the Entire Study Period | Measured starting from the first randomization and ending after the final participant is randomized (up to 100 weeks after first randomization) | Number of different counties and states represented by enrolled participants measured from the first randomization to the final randomization. | ClinicalTrials.gov |
| Other | Sustainment of intervention | Measured between 12 weeks (end of intervention) and 24 weeks after randomization | Number of intervention participants who continue to log into the contingency management/peer support app in the three months after the intervention ends as assessed through app utilization data | ClinicalTrials.gov |
| Other | Feasibility | Measured starting from the first randomization and ending after the final participant has completed the intervention, discontinued the study, or was lost to follow-up (up to 112 weeks after first randomization) | Average number of enrollments per month and percentage of enrolled participants who complete the intervention | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| R21DA066520 | Feasibility and Preliminary Effectiveness of a Remote Collaborative Care-facilitated Contingency Management-Cardiac Rehabilitation Program for People with Methamphetamine-Associated Cardiopulmonary Co | Incze, Michael; CLAPHAM, KATHARINE | UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH | NATIONAL INSTITUTE ON DRUG ABUSE | 2026 | NIH RePORTER |
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)